Cited by 1,674Breast Cancer Treatment StudiesEstrogen and related hormone effectsEndometrial and Cervical Cancer Treatments

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Cuzick, Jack, Sestak, Ivana, Baum, Michael, Buzdar, Aman, Howell, Anthony, Dowsett, Mitch, Forbes, John F·2010·The Lancet Oncology

DOI 10.1016/s1470-2045(10)70257-6

Open this paper in CoChat — free account

Abstract

Background The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage breast cancer. In this analysis, we assess the long-term outcomes after a median follow-up of 120 months.Methods We used a proportional hazards model to assess the primary endpoint of disease-free survival, and the secondary endpoints of time to recurrence, time to distant recurrence, incidence of new contralateral breast cancer, overall survival, and death with or without recurrence in all randomised patients (anastrozole n=3125, tamoxifen n=3116) and hormone-receptor-positive patients (anastrozole n=2618, tamoxifen n=2598). After treatment completion, we continued to collect data on fractures and serious adverse events in a masked fashion (safety population: anastrozole n=3092, tamoxifen n=3094). This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN18233230.Findings Patients were followed up for a median of 120 months (range 0-145); there were 24,522 woman-years of follow-up in the anastrozole group and 23,950 woman-years in the tamoxifen group. In the full study population, there were significant improvements in the anastrozole group compared with the tamoxifen group for disease-free survival (hazard ratio [HR] 0·91, 95% CI 0·83-0·99; p=0·04), time to recurrence (0·84, 0·75-0·93; p=0·001), and time to distant recurrence (0·87, 0·77-0·99; p=0·03). For hormone-receptor-positive patients, the results were also significantly in favour of the anastrozole group for disease-free survival (HR 0·86, 95% CI 0·78-0·95; p=0·003), time to recurrence (0·79, 0·70-0·89; p=0·0002), and time to distant recurrence (0·85, 0·73-0·98; p=0·02). In hormone-receptor-positive patients, absolute differences in time to recurrence between anastrozole and tamoxifen increased over time (2·7% at 5 years and 4·3% at 10 years) and recurrence rates remained significantly lower on anastrozole than tamoxifen after treatment completion (HR 0·81, 95% CI 0·67-0·98; p=0·03), although the carryover benefit was smaller after 8 years. There was weak evidence of fewer deaths after recurrence with anastrozole compared with tamoxifen treatment in the hormone-receptor-positive subgroup (HR 0·87, 95% CI 0·74-1·02; p=0·09), but there was little difference in overall mortality (0·95, 95% CI 0·84-1·06; p=0·4). Fractures were more frequent during active treatment in patients receiving anastrozole than those receiving tamoxifen (451 vs 351; OR 1·33, 95% CI 1·15-1·55; p<0·0001), but were similar in the post-treatment follow-up period (110 vs 112; OR 0·98, 95% CI 0·74-1·30; p=0·9). Treatment-related serious adverse events were less common in the anastrozole group than the tamoxifen group (223 anastrozole vs 369 tamoxifen; OR 0·57, 95% CI 0·48-0·69; p<0·0001), but were similar after treatment completion (66 vs 78; OR 0·84, 95% CI 0·60-1·19; p=0·3). No differences in non-breast cancer causes of death were apparent and the incidence of other cancers was similar between groups (425 vs 431) and continue to be higher with anastrozole for colorectal (66 vs 44) and lung cancer (51 vs 34), and lower for endometrial cancer (six vs 24), melanoma (eight vs 19), and ovarian cancer (17 vs 28). No new safety concerns were reported.Interpretation These data confirm the long-term superior efficacy and safety of anastrozole over tamoxifen as initial adjuvant therapy for postmenopausal women with hormone-sensitive early breast cancer.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(10)70257-6

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(2005) · The Lancet · doi:10.1016/s0140-6736(05)66544-0 · Cited by 7,626
Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Self-citation
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
Self-citation
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
Nabholtz, J., Buzdar, A. U., Pollak, M., Harwin, W. N., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 989
Self-citation
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Williams, N. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 918
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
Coombes, R. C., Kilburn, L., Snowdon, C. F., Paridaens, R., Coleman, R., Jones, S., Jassem, J., van de Velde, C., Delozier, T., Álvarez, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60200-1 · Cited by 901
Self-citation

Show all 27 references

Sorted by citations

Items 401–500 of 1,000

Time-varying pattern of recurrence risk for Chinese breast cancer patients
Yin, W., Di, G., Zhou, L., Lu, J., Liu, G., Wu, J., Shen, K., Han, Q., Shen, Z., & Shao, Z. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0022-5 · Cited by 42
Secondary Causes of Low Bone Mass in Patients With Breast Cancer: A Need for Greater Vigilance
Mann, G. B., Kang, Y. C., Brand, C. A., Ebeling, P. R., & Miller, J. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2549 · Cited by 42
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
Zaman, K., Thurlimann, B. J. K., Huober, J., Schönenberger, A., Pagani, O., Luthi, J., Simcock, M., Giobbie‐Hurder, A., Berthod, G., Genton, C. Y., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr448 · Cited by 42
Adjuvant Endocrine Therapy for Early Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline
Freedman, O. C., Fletcher, G. G., Gandhi, S., Mates, M., Dent, S. F., Trudeau, M., & Eisen, A. F. (2015) · Current Oncology · doi:10.3747/co.22.2326 · Cited by 41
Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
Schneider, R., Barakat, A., Pippen, J., & Osborne, C. R. C. (2011) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s22905 · Cited by 42
Active allies: hormones, stem cells and the niche in adult mammopoiesis
Joshi, P. A., Grappa, M. A. D., & Khokha, R. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.04.002 · Cited by 42
Cardiotoxicity of Molecularly Targeted Agents
Hedhli, N., & Russell, K. S. (2012) · Current Cardiology Reviews · doi:10.2174/157340311799960636 · Cited by 41
Cognitive changes associated with endocrine therapy for breast cancer
Agrawal, K., Onami, S. H., Mortimer, J. E., & Pal, S. K. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.07.004 · Cited by 41
Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial
Augustin, L. S. A., Libra, M., Crispo, A., Grimaldi, M., Laurentiis, M. D., Rinaldo, M., D’Aiuto, M., Catalano, F., Banna, G. L., Ferraù, F., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3064-4 · Cited by 46
Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer
Muluhngwi, P., & Klinge, C. M. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.004 · Cited by 41
Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen
Bertelli, G., Hall, E., Ireland, E., Snowdon, C. F., Jassem, J., Drosik, K., Karnicka-Młodkowska, H., Coombes, R. C., & Bliss, J. M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp358 · Cited by 41
Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality
Obiorah, I. E., & Jordan, V. C. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31828865a5 · Cited by 39
Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: Brief report and review of the literature
AlHilli, M. M., Long, H. J., Podratz, K. C., & Bakkum-Gamez, J. N. (2011) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2011.01698.x · Cited by 40
Precision treatment for cancer: Role of prognostic and predictive markers
Duffy, M. J., & Crown, J. P. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.865700 · Cited by 41
Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer
Litzenburger, B. C., & Brown, P. H. (2014) · Current Breast Cancer Reports · doi:10.1007/s12609-014-0144-1 · Cited by 41
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor–positive breast cancer
Schwarz, L. J., Fox, E. M., Balko, J. M., Garrett, J. T., Kuba, M. G., Estrada, M. V., Gonzalez-Angulo, A. M., Mills, G. B., Red-Brewer, M., Mayer, I. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72573 · Cited by 40
Synthesis of novel trifluoromethyl substituted furo[2,3- b ]pyridine and pyrido[3′,2′:4,5]furo[3,2- d ]pyrimidine derivatives as potential anticancer agents
Kumar, R. N., Poornachandra, Y., Punna, N., Gannarapu, M. R., Kumar, N. R., Palreddy, R., Kumar, C. G., & Narsaiah, B. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.11.007 · Cited by 40
Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis
Šeruga, B., & Amir, E. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0902-3 · Cited by 40
Linking Estrogen-Induced Apoptosis With Decreases in Mortality Following Long-term Adjuvant Tamoxifen Therapy
Jordan, V. C. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju296 · Cited by 40
Tumor characteristics and therapy of elderly patients with breast cancer
Grumpelt, A., Ignatov, A., Tchaikovski, S. N., Burger, E., Costa, S. D., & Eggemann, H. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-2111-2 · Cited by 40
Relationships between health literacy and quality of life among survivors with breast cancer
Wei, C. S., Wu, M., & Tung, H. (2021) · International Journal of Nursing Practice · doi:10.1111/ijn.12922 · Cited by 40
Symptoms of endocrine treatment and outcome in the BIG 1-98 study
Groups, F. T. B. 1.-9. C. A. I. B. C. S., Huober, J., Cole, B. F., Rabaglio, M., Giobbie‐Hurder, A., Wu, J. J., Ejlertsen, B., Bonnefoi, H. R., Forbes, J., Neven, P., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2792-7 · Cited by 41
Self-citation
Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study
Prieto‐Alhambra, D., Servitja, S., Javaid, M. K., Garrigós, L., Arden, N., Cooper, C. C., Albanell, J., Tusquets, I., Díez‐Pérez, A., & Nogués, X. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2013-9 · Cited by 40
Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer
Gonçalves, R., Ma, C. X., Luo, J. R., Suman, V. J., & Ellis, M. J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.21 · Cited by 40
Optitrain: a randomised controlled exercise trial for women with breast cancer undergoing chemotherapy
Wengström, Y., Bolam, K. A., Mijwel, S., Sundberg, C. J., Backman, M., Browall, M., Norrbom, J., & Rundqvist, H. (2017) · BMC Cancer · doi:10.1186/s12885-017-3079-x · Cited by 40
Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study
Blaes, A. H., Beckwith, H. C., Florea, N. D., Hebbel, R. P., Solovey, A. N., Potter, D. A., Yee, D., Vogel, R. I., Luepker, R. V., & Duprez, D. A. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4447-6 · Cited by 40
Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: Meta-analyses of monotherapy, sequenced therapy and extended therapy
Josefsson, M. L., & Leinster, S. (2010) · The Breast · doi:10.1016/j.breast.2009.12.010 · Cited by 39
Transcription factors and chromatin proteins as therapeutic targets in cancer
Johnston, S. J., & Carroll, J. S. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.02.002 · Cited by 41
Pain related to cancer treatments and diagnostic procedures: a no man's land?
Ripamonti, C. I., Bossi, P., Santini, D., & Fallon, M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu011 · Cited by 39
Menopausal status and adjuvant hormonal therapy for breast cancer patients: A practical guideline
Vos, F. D., van Laarhoven, H. W. M., Laven, J. S. E., Themmen, A. P. N., Beex, L. V. A. M., Sweep, F. C. G. J., Seynaeve, C., & Jager, A. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.06.005 · Cited by 39
Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study
Zembutsu, H., Nakamura, S., Akashi‐Tanaka, S., Kuwayama, T., Watanabe, C., Takamaru, T., Takei, H., Ishikawa, T., Miyahara, K., Matsumoto, H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1779 · Cited by 39
miRNA-148a regulates the expression of the estrogen receptor through DNMT1-mediated DNA methylation in breast cancer cells
Xu, Y., Chao, L., Wang, J., & Sun, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6803 · Cited by 39
A Population-Based Analysis of Breast Cancer Incidence and Survival by Subtype in Ontario Women
Seung, S. J., Traore, A. N., Pourmirza, B., Fathers, K. E., Coombes, M., & Jerzak, K. J. (2020) · Current Oncology · doi:10.3747/co.27.5769 · Cited by 40
Prognostic Value of EndoPredict in Women with Hormone Receptor–Positive, HER2-Negative Invasive Lobular Breast Cancer
Šestak, I., Filipits, M., Buus, R., Rudas, M., Balić, M., Knauer, M., Kronenwett, R., Fitzal, F., Cuzick, J. M., Gnant, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0260 · Cited by 39
Self-citation
Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
Barnadas, A., Gil, M., González, S., Tusquets, I., Muñoz-Mateu, M., Arcusa, À., Prieto, L., Vila, M. M., & Moreno, A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604868 · Cited by 39
Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence
Blok, E. J., Derks, M. G. M., van der Hoeven, J. J. M., van de Velde, C. J. �., & Kroep, J. R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.02.004 · Cited by 38
Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cells
Moy, I., Todorović, V., Dubash, A. D., Coon, J. S., Parker, J. B., Buranapramest, M., Huang, C.-C., Zhao, H., Green, K. J., & Bulun, S. E. (2014) · Oncogene · doi:10.1038/onc.2013.553 · Cited by 38
Prevention and treatment of side-effects of systemic treatment: bone loss
Body, J. J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq422 · Cited by 39
Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer
Mougalian, S. S., Epstein, L. N., Jhaveri, A. P., Han, G., Abu-Khalaf, M. M., Hofstatter, E. W., DiGiovanna, M. P., Silber, A. L. M., Adelson, K. B., Pusztai, L., et al. (2017) · JCO Clinical Cancer Informatics · doi:10.1200/cci.17.00015 · Cited by 42
ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
Zotano, Á. G., Stricker, T. P., Formisano, L., Hutchinson, K. E., Stover, D. G., Lee, K., Schwarz, L. J., Giltnane, J. M., Estrada, M. V., Jansen, V. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2904 · Cited by 38
T-Type voltage gated calcium channels: a target in breast cancer?
Bhargava, A., & Saha, S. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4970-0 · Cited by 37
Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials
Noordhoek, I., Blok, E. J., Kranenbarg, E. M., Putter, H., Carpentier, M. D., Rutgers, E. J. T., Seynaeve, C., Bartlett, J. M. S., Vannetzel, J.-M., Rea, D. W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02427 · Cited by 38
The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom
Schimdt, N., Jacob, L., Coleman, R. E., Kostev, K., & Hadji, P. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3661-3 · Cited by 38
Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women
Milani, M., Jha, G. G., & Potter, D. A. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s9 · Cited by 39
Primary endpoints for randomised trials of cancer therapy
Cuzick, J. M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60933-2 · Cited by 38
Self-citation
Fracture risk and assessment in adults with cancer
Ye, C., & Leslie, W. D. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06631-4 · Cited by 39
Molecular markers for breast cancer diagnosis, prognosis and targeted therapy
Lang, J. E., Wecsler, J. S., Press, M. F., & Tripathy, D. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23732 · Cited by 37
5‐year follow‐up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial
Wagner‐Johnston, N. D., Sloan, J. A., Liu, H., Kearns, A. E., Hines, S. L., Puttabasavaiah, S., Dakhil, S. R., Lafky, J. M., Perez, E. A., & Loprinzi, C. L. (2015) · Cancer · doi:10.1002/cncr.29327 · Cited by 37
Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients
Neuner, J. M., Yen, T. W. F., Sparapani, R., Laud, P. W., & Nattinger, A. B. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1493-x · Cited by 38
Association BetweenCYP2D6Genotypes and the Clinical Outcomes of Adjuvant Tamoxifen for Breast Cancer: A Meta-Analysis
Jung, J.-A., & Lim, H. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.221 · Cited by 37
Aromatase inhibitors in male breast cancer: a pooled analysis
Zagouri, F., Sergentanis, T. Ν., Azim, H. A., Chrysikos, D., Dimopoulos, M. A., & Ψαλτοπούλου, Θ. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3356-9 · Cited by 37
Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical Problem
Dimitrakopoulos, F.-I. D., Kottorou, A. E., Antonacopoulou, A. G., Makatsoris, T., & Kalofonos, H. P. (2015) · Journal of Breast Cancer · doi:10.4048/jbc.2015.18.3.207 · Cited by 37
Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer
Ejlertsen, B., Jensen, M., Mouridsen, H. T., & for the Danish Breast Cancer Cooperative Group (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.850738 · Cited by 36
Nomograms to estimate long-term overall survival and breast cancer-specific survival of patients with luminal breast cancer
Sun, W., Jiang, Y., Liu, Y., Ma, D., & Shao, Z.-M. (2016) · Oncotarget · doi:10.18632/oncotarget.7975 · Cited by 37
Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion
Mazumdar, A., Poage, G. M., Shepherd, J. H., Tsimelzon, A. I., Hartman, Z. C., den Hollander, P., Hill, J. L., Zhang, Y., Chang, J. C., Hilsenbeck, S. G., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3892-y · Cited by 37
Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting
Gierach, G. L., Curtis, R. E., Pfeiffer, R. M., Mullooly, M., Ntowe, E., Hoover, R. N., Nyante, S. J., Feigelson, H. S., Glass, A. G., & de González, A. B. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3340 · Cited by 37
Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study
Colzani, E., Clements, M., Johansson, A. L. V., Liljegren, A., He, W., Brand, J. S., Adolfsson, J., Fornander, T., Hall, P. N., & Czene, K. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.314 · Cited by 37
CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer
Martín‐Sánchez, E., Mendaza, S., Ulazia-Garmendia, A., Monreal‐Santesteban, I., Blanco‐Luquin, I., Córdoba, A., Vicente-García, F., Pérez‐Janices, N., Escors, D., Megı́as, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15004 · Cited by 37
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials
Galvano, A., Scaturro, D., Badalamenti, G., Incorvaia, L., Rizzo, S., Castellana, L., Cusenza, S., Cutaia, S., Santini, D., Guadagni, F., et al. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100252 · Cited by 37
Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management
Cavazza, M., Banks, H., Ercolanoni, M., Cukaj, G., Bianchi, G., Capri, G., & Longo, F. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05748-6 · Cited by 38
Cracking Open Window of Opportunity Trials
Kalinsky, K. M., & Hershman, D. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.3293 · Cited by 37
Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose–response meta‐analysis
Ghanavati, M., Khorshidi, Y., Shadnoush, M., Akbari, M. E., Ardehali, S. H., Chávarri-Guerra, Y., Akbari, A., Barragán-Carrillo, R., Amlashi, M. A., Javid, Z., et al. (2023) · Cancer Reports · doi:10.1002/cnr2.1806 · Cited by 39
Managing the toxicities of the aromatase inhibitors
Mortimer, J. E. (2009) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328334e44e · Cited by 36
Adherence to adjuvant endocrine therapy: Is it a factor for ethnic differences in breast cancer outcomes in New Zealand?
Seneviratne, S. A., Campbell, I., Scott, N., Kuper-Hommel, M. J. J., Kim, B., Pillai, A., & Lawrenson, R. A. (2014) · The Breast · doi:10.1016/j.breast.2014.11.011 · Cited by 38
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients
Ferraldeschi, R., Arnedos, M., Hadfield, K. D., A’Hern, R., Drury, S., Wardley, A. M., Howell, A., Evans, D. G., Roberts, S. A., Smith, I., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2010-z · Cited by 36
Self-citation
Hormonal therapies in young breast cancer patients: when, what and for how long?
Christinat, A., Lascio, S. D., & Pagani, O. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.05.25 · Cited by 36
Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study
Pan, Y., Heisig, S. R., von Blanckenburg, P., Albert, U., Hadji, P., Rief, W., & Nestoriuc, Y. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4637-2 · Cited by 35
Regulation of aromatase in cancer
Molehin, D., Rasha, F. A., Rahman, R. L., & Pruitt, K. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04099-0 · Cited by 36
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial
Boccardo, F., Guglielmini, P., Bordonaro, R., Fini, A., Massidda, B., Porpiglia, M., Roagna, R., Serra, P., Orzalesi, L., Ucci, G., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.025 · Cited by 36
A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer
Lin, Y., Liu, J., Zhang, X., Li, L., Hu, R., Liu, J., Deng, Y., Chen, D., Zhao, Y., Sun, S., et al. (2014) · Cancer Science · doi:10.1111/cas.12474 · Cited by 36
Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer
Iwase, H. (2008) · Breast Cancer · doi:10.1007/s12282-008-0071-y · Cited by 36
Hydroxybenzothiazoles as New Nonsteroidal Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1)
Spadaro, A., Negri, M., Marchais‐Oberwinkler, S., Bey, E., & Frotscher, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029252 · Cited by 36
Impact of adjuvant anti-estrogen therapies (tamoxifen and aromatase inhibitors) on perioperative outcomes of breast reconstruction
Billon, R., Bosc, R., Belkacémi, Y., Assaf, E., SidAhmed‐Mezi, M., Hersant, B., & Meningaud, J. (2017) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2017.05.046 · Cited by 35
ACOG Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice
(2018) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000002640 · Cited by 36
Incidence of metachronous contralateral breast cancer in Denmark 1978–2009
Rasmussen, C. B., Kjær, S. K., Ejlertsen, B., Andersson, M., Jensen, M., Christensen, J., Langballe, R., & Mellemkjær, L. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyu202 · Cited by 35
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy
Hines, S. L., Sloan, J. A., Atherton, P. J., Perez, E. A., Dakhil, S. R., Johnson, D. B., Reddy, P. S., Dalton, R. J., Mattar, B. I., & Loprinzi, C. L. (2010) · The Breast · doi:10.1016/j.breast.2009.12.001 · Cited by 36
The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy
Fan, P., Maximov, P. Y., Curpan, R. F., Abderrahman, B., & Jordan, V. C. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.004 · Cited by 36
Systemic Therapy in Breast Cancer
Corti, C., Batra-Sharma, H., Kelsten, M. F., Shatsky, R. A., Garrido-Castro, A. C., & Gradishar, W. J. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432442 · Cited by 38
Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells
van Agthoven, T., Dorssers, L. C. J., Lehmann, U., Kreipe, H. H., Looijenga, L. H. J., & Christgen, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136845 · Cited by 34
Current role and safety profile of aromatase inhibitors in early breast cancer
Tomao, F., Spinelli, G., Vici, P., Codacci-Pisanelli, G., Cascialli, G., Frati, L., Panici, P. B., & Tomao, S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.96 · Cited by 34
Breast Cancer and Osteoporosis - Management of Cancer Treatment-Induced Bone Loss in Postmenopausal Women with Breast Cancer
Kalder, M., & Hadji, P. (2014) · Breast Care · doi:10.1159/000368843 · Cited by 38
Cost Effectiveness of Fracture Prevention in Postmenopausal Women Who Receive Aromatase Inhibitors for Early Breast Cancer
Ito, K., Blinder, V. S., & Elkin, E. B. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7001 · Cited by 34
Predictive algorithms for adjuvant therapy: TransATAC
Dowsett, M., Salter, J., Zabaglo, L. A., Mallon, E., Howell, A., Buzdar, A. U., Forbes, J., Pineda, S., & Cuzick, J. M. (2011) · Steroids · doi:10.1016/j.steroids.2011.02.032 · Cited by 34
Self-citation
Pilot Trial of Preoperative (Neoadjuvant) Letrozole in Combination With Bevacizumab in Postmenopausal Women With Newly Diagnosed Estrogen Receptor— or Progesterone Receptor—Positive Breast Cancer
Forero, A., Saleh, M. N., Galleshaw, J. A., Jones, C., Shah, J. J., Percent, I. J., Nabell, L. M., Carpenter, J. T., Falkson, C. I., Krontiras, H., et al. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.035 · Cited by 34
Surveillance Mammography in Older Patients With Breast Cancer—Can We Ever Stop?
Freedman, R. A., Keating, N. L., Partridge, A. H., Muss, H. B., Hurria, A., & Winer, E. P. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3931 · Cited by 34
Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer
Taxel, P., Faircloth, E. L., Idrees, S., & Poznak, C. H. V. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00052 · Cited by 34
The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression
Mazumdar, A., Tahaney, W. M., Bollu, L. R., Poage, G. M., Hill, J. L., Zhang, Y., Mills, G. B., & Brown, P. H. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0118-6 · Cited by 34
Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates
Moncusí, M. P., García‐Giralt, N., Díez‐Pérez, A., Servitja, S., Tusquets, I., Prieto‐Alhambra, D., & Nogués, X. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3886 · Cited by 34
Rational approaches of drug design for the development of selective estrogen receptor modulators (SERMs), implicated in breast cancer
Makar, S., Saha, T., Swetha, R., Gutti, G., Kumar, A., & Singh, S. K. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103380 · Cited by 34
Early Breast Cancer in the Older Woman
Vanderwalde, A. M., & Hurria, A. (2011) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2011.10.002 · Cited by 34
Adjuvant endocrine therapy for premenopausal women with breast cancer
Puhalla, S., Brufsky, A., & Davidson, N. E. (2009) · The Breast · doi:10.1016/s0960-9776(09)70286-3 · Cited by 34
Mammographic Breast Density Response to Aromatase Inhibition
Vachon, C. M., Suman, V. J., Brandt, K. R., Kosel, M., Buzdar, A. U., Olson, J. E., Wu, F.-F., Flickinger, L. M., Ursin, G., Elliott, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2789 · Cited by 34
Self-citation
Tamoxifen: the drug that came in from the cold
Hughes‐Davies, L., Caldas, C., & Wishart, G. C. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605231 · Cited by 34
Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications
Masri, J. E., & Phadke, S. D. (2022) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000721 · Cited by 35
Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab
Lipton, A., Smith, M. R., Ellis, G. K., & Goessl, C. D. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s8511 · Cited by 33
Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer
Kyvernitakis, I., Rachner, T. D., Urbschat, A., Hars, O., Hofbauer, L. C., & Hadji, P. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1726-z · Cited by 33
Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population‐based study
Kamaraju, S., Shi, Y., Smith, E. C., Nattinger, A. B., Laud, P. W., & Neuner, J. M. (2018) · Clinical Cardiology · doi:10.1002/clc.23114 · Cited by 33
Cancer of the Breast
Henry, N. L., Shah, P. D., Haider, I., Freer, P. E., Jagsi, R., & Sabel, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00088-8 · Cited by 37
Breast cancer
Chopra, S., & Davies, E. L. (2019) · Medicine · doi:10.1016/j.mpmed.2019.11.009 · Cited by 33
Recent insights into the effects of metabolism on breast cancer cell dormancy
Bartlome, S., & Berry, C. C. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01869-5 · Cited by 34

Authors: Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F.
Affiliations: University of London (GB)
Cancer Research UK (GB)
The University of Texas MD Anderson Cancer Center (US)
Royal Marsden Hospital (GB)
University of Newcastle Australia (AU)
Corresponding author: Cuzick, Jack
ORCID: Cuzick, Jack
Baum, Michael
Buzdar, Aman
Howell, Anthony
Dowsett, Mitch
Forbes, John F
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2010-12
Volume: 11
Issue: 12
Pages: 1135-1141
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(10)70257-6
OpenAlex: W2112780046
Cited by: 1,674
References: 27
Citations by year: 2026: 21 · 2025: 35 · 2024: 50 · 2023: 54 · 2022: 63 · 2021: 64 · 2020: 85 · 2019: 66 · 2018: 85 · 2017: 98 · 2016: 101 · 2015: 116 · 2014: 125 · 2013: 148 · 2012: 121
FWCI: 51.63
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Research Explorer (The University of Manchester) (submittedVersion)
NOVA (University of Newcastle Australia) (submittedVersion)
Funders: AstraZeneca
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords: anastrozole, tamoxifen, adjuvant endocrine therapy, early breast cancer, postmenopausal women, disease-free survival, time to recurrence, distant recurrence, hormone receptor-positive breast cancer, contralateral breast cancer, overall survival, fracture risk, long-term outcomes, ATAC trial, aromatase inhibitors, selective estrogen receptor modulators, breast cancer recurrence
MeSH terms: Anastrozole, Administration, Oral, Breast Neoplasms, Female, Follow-Up Studies, Humans, Neoplasm Staging, Nitriles, Tamoxifen, Triazoles, Treatment Outcome, Chemotherapy, Adjuvant, Postmenopause, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks